Metabolic dysfunction–associated steatohepatitis (MASH) is the new term for non-alcoholic steatohepatitis (NASH). There are ...

NASH becomes MASH as medical experts replace stigmatizing "non-alcoholic" liver disease terminology with dignity-focused ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

A recommended 150 minutes per week at moderate intensity can help reduce liver inflammation and rid the organ of fat. Antioxidants and other compounds in coffee (even decaf) can help protect against ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Mar. 11, 2025 — Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder ... Novel Therapeutics of Nonalcoholic Fatty Liver Diseases Mar. 6, 2025 — Investigators have ...